Abstract
Effect of irbesartan, an angiotensin II receptor antagonist, was studied in streptozotocin (STZ) induced diabetic nephropathy. Polyuria, proteinuria, blood urea, creatinine clearance, and urinary electrolytes were determined to assess kidney damage. There was a significant increase in urine volume, urinary protein and blood urea in STZ induced diabetic rats. On the other hand, irbesartan treatment resulted in a significant reduction in urinary protein and blood urea in these rats. Irbesartan treatment also improved creatinine clearance and exhibited a natriuretic effect in these animals. Results suggest that irbesartan treatment ameliorate STZ induced diabetic nephropathic changes, in rats.
Key Words: Irbesartan, Diabetic nephropathy, Streptozotocin
Full Text
The Full Text of this article is available as a PDF (57.8 KB).
References
- 1.Lippert J., Rit E., Schwarzbeck A., Schneider P. The rising tide of ESRF from diabetic nephropathy type II and epidemiological analysis. Nephrol Dial Transplant. 1995;10:462–467. doi: 10.1093/ndt/10.4.462. [DOI] [PubMed] [Google Scholar]
- 2.Parving H., Jacobsen P., Rossing K., Smidth U.M., Hommel E., Rossing P. Benefits of long term antihypertensive treatment on the prognosis in diabetic nephropathy. Kidney Int. 1986;49:1779–1782. doi: 10.1038/ki.1996.266. [DOI] [PubMed] [Google Scholar]
- 3.Lewis E.L., Hunsicker L.G., Bain R.P., Rohde R.D. The effect of angiotensin converting enzyme inhibitors on diabetic nephropathy. N Eng J Med. 1983;329:1456–1462. doi: 10.1056/NEJM199311113292004. [DOI] [PubMed] [Google Scholar]
- 4.Kasiske B.L., Lakatura J.D., Ma J.Z., Lousis T.A. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis. 1998;31:954–961. doi: 10.1053/ajkd.1998.v31.pm9631839. [DOI] [PubMed] [Google Scholar]
- 5.Krolewski A.S., Warram J.H., Christilieb A.R. Hypercholesterolemia — A determinant of renal function loss and deaths in IDDM and nephropathy. Kidney Int. 1994;45:S125–S131. [PubMed] [Google Scholar]
- 6.Parving H., Lehnert H., Brochner-Mortansen J., Gomis R., Anderson S., Arner P. The effect of irbesartan on the d3velopment of diabetic nephropathy in patients with type 2 diabetes. N Eng J Med. 2001;345:870–878. doi: 10.1056/NEJMoa011489. [DOI] [PubMed] [Google Scholar]
- 7.Hostetter T.H. Prevention of end-stage renal disease due to type 2 diabetes. N Eng J Med. 2001;345:910–901. doi: 10.1056/NEJM200109203451209. [DOI] [PubMed] [Google Scholar]
- 8.Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem. 1969;6:24–27. [Google Scholar]
- 9.Johnson M.A., Rohlfs E.M., Silverman L.M. Determination of proteins in urine. In: Burtis C.A., Ashwood E.R., editors. Teitz Textbook of Clinical Chemistry. 3rd Ed. Philadelphia: WB Saunders; 1999. pp. 525–526. [Google Scholar]
- 10.Marsh W.H., Fingerhut B., Miller H. Automated and manual direct methods for the determination of blood urea. Clin Chem. 1965;11:624–627. [PubMed] [Google Scholar]
- 11.Newman D.J., Prince C.P. Renal function and nitrogen metabolites. In: Burtis C.A., Ashwood E.R., editors. Teitz Textbook of Clinical Chemistry. 3rd Ed. Philadelphia: WB Saunders; 1990. pp. 1204–1210. [Google Scholar]